Stay updated with breaking news from Alanh Bryce. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.
For patients with metastatic castration-resistant prostate cancer with BRCA alterations, rucaparib doubled progression-free survival as compared with docetaxel, abiraterone, or enzalutamide.
Clovis Oncology, Inc. today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation... | October 27, 2022
Mayo Clinic Cancer Center in Phoenix developed and implemented a new system that allows chemotherapy infusions to be scheduled throughout the day.The initiative — described in a paper published in JCO Oncology Practice — prevents mid-day crowding in infusion facilities.